The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Alexion Pharmaceuticals Inc

Nasdaq: ALXN
Last

(U.S.) $144.37

Today's change+3.84 +2.73%
Updated May 3 4:00 PM EDT. Delayed by at least 15 minutes.
 

Alexion Pharmaceuticals Inc

Nasdaq: ALXN
Last

(U.S.) $144.37

Today's change+3.84 +2.73%
Updated May 3 4:00 PM EDT. Delayed by at least 15 minutes.

Alexion Pharmaceuticals Inc crosses above 50-day moving average

Alexion Pharmaceuticals Inc closed up sharply Tuesday, rallying (U.S.)$3.84 or 2.73% to (U.S.)$144.37 and crossing above its 50-day moving average. Over the last five days, shares have lost 6.26% and are down 24.31% for the last year to date. This security has underperformed the S&P 500 by 14.18% during the last year.

Key company metrics

  • Open(U.S.) $141.71
  • Previous close(U.S.) $140.53
  • High(U.S.) $147.79
  • Low(U.S.) $141.00
  • Bid / Ask(U.S.) $144.38 / (U.S.) $157.51
  • YTD % change-24.31%
  • Volume2,259,306
  • Average volume (10-day)1,488,522
  • Average volume (1-month)1,570,432
  • Average volume (3-month)1,737,034
  • 52-week range(U.S.) $124.16 to (U.S.) $208.88
  • Beta0.87
  • Trailing P/E201.11×
  • P/E 1 year forward27.81×
  • Forward PEG1.41×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $0.72
Updated May 3 4:00 PM EDT. Delayed by at least 15 minutes.
S&P TSX1.14%Sector:HealthcareIndustry:Biotechnology

Latest Press Releases

View more Press Releases
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2016Q4/2015Q3/2015Q2/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015
Revenue701701667636
Total other revenue--------
Total revenue701701667636
Gross profit642643613584
Total cost of revenue59585452
Total operating expense535604512455
Selling / general / administrative233242213221
Research & development176191161126
Depreciation / amortization8080416
Interest expense (income), net operating--------
Unusual expense (income)-13334350
Other operating expenses, total--------
Operating income16697155181
Interest income (expense), net non-operating-24-23----
Gain (loss) on sale of assets--------
Other--------
Income before tax14475139177
Income after tax9267-184170
Income tax, total5183237
Net income9267-184170
Total adjustments to net income--------
Net income before extra. items9267-184170
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items9267-184170
Inc. avail. to common incl. extra. items9267-184170
Diluted net income9267-184170
Dilution adjustment--------
Diluted weighted average shares225228226205
Diluted EPS excluding extraordinary itemsvalue per share0.410.29-0.810.83
Dividends per sharevalue per share----0.000.00
Diluted normalized EPSvalue per share0.370.42-0.691.07